Evaluation of Response to Treatment of Helicobacter Pylori Infection in Portal Hypertensive HCV Cirrhotic Patients

Authors mohamed gamal abdrabu 1 Hussien mahmoud Saad 2 hanaa elhoushy 3 sara asar 4 1 lecturer at tropical medicine department,alexandria faculty of medicine 2 internal medicine department.GIT unit,faculty of medicine .Alexandria university 3 Department of Medical Education, Faculty of Medicine Alexandria University, Alexandria, Egypt 4 Medical Microbiology and Immunology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt 10.21608/ajgh.2025.400335.1087 Abstract Background: Helicobacter pylori is an etiology of various gastrointestinal disorders such as chronic gastritis, peptic ulcer, and stomach cancer. Aim: The aim was to assess the response to Helicobacter pylori treatment in patients with portal hypertensive hepatitis C virus (HCV) cirrhosis. Methods: two groups; Group A (case group): 52 H. pylori-positive HCV portal hypertensive cirrhotic cases. Group B (control group): 52 H. pylori-positive non-portal hypertensive, non-cirrhotic individuals. Both groups were given levofloxacin-based therapy (Levofloxacin 500 mg / Amoxicillin 1 g bid/ Pantoprazole 40 mg bid) for 2 weeks. The H. pylori stool antigen test was repeated 4 weeks after treatment. Results: A statistically significant difference was obtained regarding H. pylori antigen testing before and after treatment in the control group compared to the case group. Conclusion: H. pylori infection is associated with a better treatment response in non-cirrhotic, non-portal hypertensive patients compared to those with HCV-cirrhosis and portal hypertension.